Research Article
Serum Interleukin-23 in Polish Patients with Systemic Lupus Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral Vascular Disease
Table 5
Serological characteristics of systemic lupus erythematosus patients and healthy controls.
| Autoantibody | Systemic lupus erythematosus patients (%) | Healthy controls (%) |
| Antinuclear antibodies IgG | 73 (77.7%) | 2 (7.4%) | Anti-double stranded DNA IgG | 37 (39.4%) | 0 (0.0%) | Anti-nucleosome IgG | 30 (31.9%) | 0 (0.0%) | Anti-Sm IgG | 4 (4.3%) | 0 (0.0%) | Anti-SS-A/Ro IgG | 42 (44.7%) | 0 (0.0%) | Anti-SS-B/La IgG | 14 (14.9%) | 0 (0.0%) | Anti-ribosomal P protein IgG | 6 (6.4%) | 0 (0.0%) | Anti-histone IgG | 19 (20.2%) | 0 (0.0%) | Anti-U1-RNP IgG | 20 (21.3%) | 0 (0.0%) | Anti-cardiolipin IgG | 33 (35.1%) | 0 (0.0%) | Anti-cardiolipin IgM | 19 (20.2%) | 1 (3.7%) | Anti-cardiolipin IgA | 40 (42.6%) | 1 (3.7%) | Anti-beta2-glycoprotein I IgG | 7 (7.4%) | 0 (0.0%) | Anti-beta2-glycoprotein I IgM | 23 (24.5%) | 1 (3.7%) | Anti-beta2-glycoprotein I IgA | 23 (24.5%) | 0 (0.0%) | Anti-oxidized low-density lipoprotein IgG | 45 (47.9%) | 0 (0.0%) | Anti-oxidized low-density lipoprotein IgM | 68 (72.3%) | 0 (0.0%) | Anti-prothrombin IgG | 10 (10.6%) | 0 (0.0%) | Anti-prothrombin IgM | 12 (12.8%) | 0 (0.0%) | Anti-prothrombin IgA | 11 (11.7%) | 0 (0.0%) | Anti-phosphatidylserine IgG | 7 (7.4%) | 0 (0.0%) | Anti-phosphatidylserine IgM | 6 (6.4%) | 1 (3.7%) | Anti-phosphatidylethanolamine IgG | 12 (12.8%) | 0 (0.0%) | Anti-phosphatidylethanolamine IgM | 6 (6%) | 0 (0.0%) | Lupus anticoagulant | 15 (16.0%) | 0 (0.0%) | Anti-neutrophil cytoplasmic antibodies IgG | 39 (41.5%) | 2 (7.4%) | Anti-proteinase 3 IgG | 0 (0.0%) | 0 (0.0%) | Anti-myeloperoxidase IgG | 9 (9.6%) | 0 (0.0%) | Anti-lactoferrin IgG | 12 (12.8%) | 0 (0.0%) | Anti-elastase IgG | 9 (9.6%) | 0 (0.0%) | Anti-BPI IgG | 1 (1.1%) | 0 (0.0%) | Anti-endothelial cell antibody IgG | 42 (44.7%) | 3 (11.1%) |
|
|
BPI: bactericidal/permeability-increasing protein.
|